AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals has submitted the CRISIL Ratings Limited Monitoring Agency Report for Q3 FY26 regarding use of IPO proceeds raised in July-August 2024. The company raised gross proceeds of Rs 6,800 million, with net proceeds of Rs 6,373.70 million after issue expenses of Rs 426.30 million. All five objects of the IPO — repayment of company debt (Rs 1,599.10 million), repayment of subsidiary debt (Rs 2,270.90 million), working capital funding (Rs 550 million), acquisitions (Rs 278.70 million), and general corporate purposes (Rs 1,675 million) — have been fully utilized, with each completed in or before the June 2025 quarter. Only Rs 49.07 million remains unutilized in the public offer account toward pending issue expenses. No deviations from the stated objects, no delays, and no major changes were reported.
This is a routine compliance filing confirming that Akums has used its IPO funds exactly as promised to investors. With full deployment of proceeds and no deviations, there is no negative signal for shareholders. The remaining Rs 49.07 million in issue expenses is small and immaterial.